SynthesisEuropean journal of nutrition2019
Effects of products designed to modulate the gut microbiota on hyperlipidaemia.
Synthesis in European journal of nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Gut microbiota is a potential goalkeeper of dyslipidemia.Frontiers in endocrinology · 2022Pooled it
- Comparative effects of periodontitis - versus periodontal health-derived saliva on systemic lipid metabolism in mice: mediation through oral-gut axis.Journal of oral microbiology · 2026Article
- Alterations in bile acid metabolites associated with pathogenicity and IVIG resistance in Kawasaki disease.Frontiers in cardiovascular medicine · 2025Article
- Dates fruit effects on dyslipidemia among patients with Type-2 diabetes mellitus: A systematic review and meta-analysis of randomized trials.Pakistan journal of medical sciences · 2025Review
- Variations in the Relative Abundance of Gut Bacteria Correlate with Lipid Profiles in Healthy Adults.Microorganisms · 2023Article
- Effect of macadamia oil cake on blood lipid characteristics and intestinal microbiota in hyperlipidemic rat.Food science & nutrition · 2023Article
- Bacteroides vulgatus Ameliorates Lipid Metabolic Disorders and Modulates Gut Microbial Composition in Hyperlipidemic Rats.Microbiology spectrum · 2023Article
- The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.International journal of molecular sciences · 2023Review
- Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders.Frontiers in nutrition · 2023Review
- Influence of high-fat diet on host animal health via bile acid metabolism and benefits of oral-fed Streptococcus thermophilus MN-ZLW-002.Experimental animals · 2022Article
- Article
- Gut Microbiota and Serum Metabolome in Elite Cross-Country Skiers: A Controlled Study.Metabolites · 2022Article
- Gut microbiota signature as predictors of adverse outcomes after acute ischemic stroke in patients with hyperlipidemia.Frontiers in cellular and infection microbiology · 2022Article
- Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet.Frontiers in nutrition · 2022Article
- FermentedFrontiers in pharmacology · 2022Article
- Interactions between the Gut Microbiome, Lung Conditions, and Coronary Heart Disease and How Probiotics Affect These.International journal of molecular sciences · 2021Review
- Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia.Frontiers in cellular and infection microbiology · 2021Review
- Hypolipidemic Effects of Fermented Seaweed Extracts byFrontiers in microbiology · 2021Article
- Gut Microbiota and Atherosclerosis-Focusing on the Plaque Stability.Frontiers in cardiovascular medicine · 2021Review
- Probiotics, Prebiotics and Synbiotics-A Promising Strategy in Prevention and Treatment of Cardiovascular Diseases?International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeFatalities due to heart and cerebrovascular diseases caused by uncontrolled hyperlipidaemia increase every year; on the other hand, lipid-lowering drugs are known to cause side effects. The gut microbiota has been thoroughly investigated by researchers and consumers, because they have unique functional properties and littler side effects. However, the effects of the gut microbiota remain controversial. We conducted a meta-analysis to assess the effects of products designed to modulate the gut microbiota on various hyperlipidaemias.
methodsWe systematically searched PubMed, Embase, Cochrane Library (Central), and Web of Science for randomized controlled trials (published before June 2017, and those only in English) to compare treatment (products designed to modulate the gut microbiota) versus placebo. Our main endpoints were total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in serum. We assessed pooled data using a fixed effects model.
resultsOf 1337 identified studies, 21 were eligible and included in our analysis (n = 1436 participants). The combined estimate of effect size for the impact of products designed to modulate the gut microbiota on serum TC (WMD - 11.07 mg/dL, 95% CI - 13.72 to - 8.43, p < 0.001), LDL-C (WMD - 10.96 mg/dL, 95% CI - 13.37 to - 8.56, p < 0.001), and HDL-C (WMD 0.72 mg/dL, 95% CI 0.06-1.38, p = 0.032) were statistically significant, while no significant effect was found on TG concentrations (WMD - 0.56 mg/dL, 95% CI - 5.59 to 4.47, p = 0.828). Subgroup analysis showed parallel trials, probiotics, and long-term intervention had better effects on lowering blood lipid levels.
conclusionProducts designed to modulate the gut microbiota results in changes of the plasma lipid concentrations and these changes may protect against cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.